NASDAQ · HTFL
Heartflow, Inc. Common Stock
$60.53+$1.43 (+2.42%)
Heartflow, Inc. Common Stock’s quoted price sits in the upper half of its reported 52-week range, 0.05% below the high.
Loading market information…
NYSE · PBH · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Prestige Consumer Healthcare Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.41% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
BEHIND THE RESULTS
Prestige Consumer Healthcare Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of $1.07. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Prestige Consumer Healthcare Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:14 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2025 | May 8, 2025 | $1.32+1.54% vs estimate | $296.76M+9.74% vs estimate |
|---|
| Q3 2025 | Feb 6, 2025 | $1.22+5.17% vs estimate | $290.32M+0.18% vs estimate |
|---|
| Q2 2025 | Nov 7, 2024 | $1.09+0.93% vs estimate | $283.55M+0.52% vs estimate |
|---|
THE ANALYST VIEW
17 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$60.53+$1.43 (+2.42%)
Heartflow, Inc. Common Stock’s quoted price sits in the upper half of its reported 52-week range, 0.05% below the high.
$41.25+$0.66 (+1.63%)
Concentra Group Holdings Parent, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.29% below the high.
$81.25+$0.59 (+0.73%)
LivaNova PLC’s quoted price sits in the upper half of its reported 52-week range, 5.26% below the high.
$168.65+$2.26 (+1.36%)
ICU Medical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.55% below the high.
$22.30-$0.23 (-1.02%)
Legend Biotech Corporation’s quoted price sits in the lower half of its reported 52-week range, 40.53% below the high.
$31.49$0.00 (0.0%)
Catalyst Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.29% below the high.
$82.84-$0.36 (-0.43%)
Disc Medicine, Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.74% below the high.
$22.00+$0.16 (+0.71%)
Privia Health Group, Inc.’s quoted price sits in the lower half of its reported 52-week range, 23.68% below the high.
